NCT02983006 2021-10-18
Study of DS-8273a With Nivolumab in Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 1 Completed
Clinical Trials
3 trialsNCT02076451 2019-02-12
Open-label Study of DS-8273a to Assess Its Safety and Tolerability, and Assess Its Pharmacokinetic and Pharmacodynamic Properties in Subjects With Advanced Solid Tumors or Lymphomas
Daiichi Sankyo
Phase 1 Completed
NCT02991196 2019-02-12
Antibody DS-8273a Administered in Combination With Nivolumab in Subjects With Advanced Colorectal Cancer
Daiichi Sankyo
Phase 1 Terminated